Physician profile
Mark Lagatta
NPI 1821081985
$15,425.22
in general payments reported to CMS, 2019-2025
43 companies · $2,858 in 2025
The $2,858 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,327 · 2020: $1,326 · 2021: $1,805 · 2022: $2,324 · 2023: $2,679 · 2024: $3,106 · 2025: $2,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,287 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,286.53 |
| Education | $357.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $3,041.95 | 2019-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $2,406.66 | 2020-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals Lp | $1,424.31 | 2019-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $1,019.85 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $751.54 | 2021-2025 | |
| Vifor Pharma, INC. | $698.72 | 2019-2025 | Veltassa |
| Mallinckrodt Enterprises LLC | $657.08 | 2019 | |
| Calliditas Therapeutics US INC. | $598.43 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $469.42 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $451.06 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $443.35 | 2022-2025 | Krystexxa, Tavneos, Uplizna |
| Ani Pharmaceuticals, INC. | $426.75 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $393.14 | 2020-2023 | Krystexxa, Duexis |
| Ardelyx, INC. | $304.37 | 2023-2025 | Ibsrela |
| Baxter Healthcare | $294.27 | 2019-2024 | Renal - Pd |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lagatta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.